Acadian Asset Management LLC Has $1.16 Million Stock Holdings in Nkarta, Inc. $NKTX

Key Points

• Acadian Asset Management LLC has reduced its stake in Nkarta, Inc. by 25.9%, selling 220,423 shares and now holding approximately 0.89% of the company.
• Jefferies Financial Group Inc. significantly increased its position in Nkarta by 901.7%, now owning 2,504,219 shares worth $6,236,000.
• Nkata's current stock price is at $1.99 with a 1-year low of $1.31 and a high of $5.68, while analysts maintain a consensus rating of "Buy" with a target price of $13.60.

Acadian Asset Management LLC lowered its stake in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 25.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 629,378 shares of the company's stock after selling 220,423 shares during the quarter. Acadian Asset Management LLC owned approximately 0.89% of Nkarta worth $1,156,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC acquired a new position in Nkarta during the 1st quarter valued at approximately $32,000. Bank of America Corp DE boosted its position in Nkarta by 110.1% during the 4th quarter. Bank of America Corp DE now owns 380,444 shares of the company's stock worth $947,000 after acquiring an additional 199,345 shares during the period. Deutsche Bank AG boosted its position in Nkarta by 26.1% during the 4th quarter. Deutsche Bank AG now owns 43,157 shares of the company's stock worth $107,000 after acquiring an additional 8,946 shares during the period. Wellington Management Group LLP boosted its position in Nkarta by 4.1% during the 4th quarter. Wellington Management Group LLP now owns 225,224 shares of the company's stock worth $561,000 after acquiring an additional 8,883 shares during the period. Finally, Nuveen Asset Management LLC boosted its position in Nkarta by 18.3% during the 4th quarter. Nuveen Asset Management LLC now owns 140,113 shares of the company's stock worth $349,000 after acquiring an additional 21,627 shares during the period. Institutional investors and hedge funds own 80.54% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on NKTX. Stifel Nicolaus reduced their price target on Nkarta from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. Wall Street Zen upgraded Nkarta from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Needham & Company LLC reiterated a "buy" rating and set a $10.00 price target on shares of Nkarta in a research report on Wednesday, August 13th. Finally, Mizuho reduced their price target on Nkarta from $16.00 to $14.00 and set an "outperform" rating for the company in a research report on Tuesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $13.60.

Nkarta Price Performance

Shares of Nkarta stock traded up $0.01 during trading on Friday, hitting $2.00. The stock had a trading volume of 1,796,895 shares, compared to its average volume of 563,694. The firm has a market cap of $142.06 million, a P/E ratio of -1.35 and a beta of 0.76. The business has a fifty day moving average of $2.10 and a two-hundred day moving average of $1.90. Nkarta, Inc. has a fifty-two week low of $1.31 and a fifty-two week high of $5.40.

Nkarta (NASDAQ:NKTX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.06. As a group, research analysts forecast that Nkarta, Inc. will post -1.7 earnings per share for the current year.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.